摘要
目的检测肝细胞癌患者手术治疗前后血清可溶性E-钙黏连蛋白(sEC)的表达及其临床意义,并监测其在复发中的价值。方法检测105例肝细胞癌患者手术前后及70例健康人sEC的水平,分析术前sEC水平与临床病理特征的关系,并对手术后复发的47例肝癌患者的sEC水平进行回顾性研究分析。结果肝细胞癌患者术前sEC水平显著高于健康人,手术1周后sEC水平较术前显著下降。术前sEC水平与肝细胞癌TNM分期密切相关(P<0.01),与肿瘤分级、有无门静脉癌栓、有无包膜相关(P<0.05),与年龄、肿瘤大小无关(P>0.05)。当确诊为肝癌复发时,sEC水平明显也高于术后(P<0.01)。结论肝细胞癌术前sEC水平与临床分期有关,可作为一种肝细胞癌预后和复发预测因子。
Objective To detect the expression levels of serum soluble E-cadherin(sEC) before and after operation in hepatocellular carcinoma(HCC) patients and to monitor postoperative recurrence of HCC. Methods The levels of sEC in 105 HCC patients were tested by enzyme linked immunosorbent assay(ELISA) before and after operation as well as in 70 healthy controls. Their correlations with clinical and pathological factors were also analyzed. Retrospectively the level of plasma sEC of 47 patients who had been suffered from the HCC operation and relapse were also analyzed. Results The levels of sEC in hepatocellular carcinoma(HCC) patients before operation were significantly higher than those in controls. Which declined signifi cantly one week after operation.The sEC levels before operation showed signifi cant correlation with TNM stages(P<0.01), Edmondson grade, the cancerous thrombi within the portal vein and the capsule of carcinoma(P<0.05), but not with age of patients or tumor size(P>0.05). Conclusion The levels of sEC in HCC patients before operation is closely related with clinical stages, which may be a predictive factor for prognosis and recurrence of HCC.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2014年第2期153-156,共4页
Cancer Research on Prevention and Treatment
基金
广西壮族自治区卫生厅计划课题资助项目(Z2009313)
